Health
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar ® Gel) for Persistently Active Systemic Lupus Erythematosus – DocWire News
Introduction: We assessed patient-reported outcomes from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin
Introduction: We assessed patient-reported outcomes from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection (RCI; Acthar® Gel) in patients with persistently active systemic lupus erythematosus (SLE) despite treatment with moderate-dose glucocorticoids.
Methods: The trial enrolled adults with active SLE and moderate-to-severe rash and/or arthritis despite use of stable glucocorticoids (7.5 mg/day to 30 mg/day prednisone equivalent), antimalarials,…
-
Noosa News17 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business18 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Noosa News20 hours agoNo conviction recorded for teen behind attack on Peter Dutton’s office
-
Noosa News20 hours ago‘They’re not taking the concerns of women seriously’